Pharmaceuticals News and Research

RSS

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure

17 Jul 2014

New article describes about crowdsourcing and drug repurposing needs

Experimental drugs proven safe but perhaps not sufficiently effective in initial testing or against a first disease target may sit gathering dust on the shelves of pharmaceutical companies.

17 Jul 2014

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF).

17 Jul 2014

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to U.S. healthcare providers. This is the first shipment of GSK’s U.S. flu vaccine supply for the flu season, following licensing and lot-release approval from the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research.

17 Jul 2014

More insurers want you to see a doctor virtually

Insurers like WellPoint and Aetna are offering patients the option of e-visits with doctors as a way to cut costs, but some see problems with that, reports Bloomberg. Other media outlets explore the controversy over Sovaldi, an expensive new drug for hepatitis C.

17 Jul 2014

Single injection of protein FGF1 enough to restore blood sugar levels

In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days.

17 Jul 2014

Scientists build artificial cells programmed to eat their undesirable neighbors

A team of researchers has devised a Pac-Man-style power pellet that gets normally mild-mannered cells to gobble up their undesirable neighbors. The development may point the way to therapies that enlist patients’ own cells to better fend off infection and even cancer, the researchers say. A description of the work will be published July 15 in the journal Science Signaling.

16 Jul 2014

Virobay announces closing of expanded Series B second tranche financing

Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million.

16 Jul 2014

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

16 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

Significant percentage of completed drug clinical trials are not disclosed to public

A significant percentage of completed drug clinical trials, especially those funded by industry, are not disclosed to the public, years after being completed-a trend that "threatens the validity of the clinical research literature in the U.S.," according to a study led by a Boston University School of Public Health (BUSPH) researcher.

16 Jul 2014

Research shows promise to speed up drug discovery for deadly diseases

Antibiotic resistance is depleting our arsenal against deadly diseases and infections, such as tuberculosis and Staph infections, but recent research shows promise to speed up the drug discovery process.

16 Jul 2014

Research sheds new light on brain's complicated barrier tissue

Research from the University of Copenhagen is shedding new light on the brain's complicated barrier tissue. The blood-brain barrier is an effective barrier which protects the brain, but which at the same time makes it difficult to treat diseases such as Alzheimer's.

16 Jul 2014

New femtosecond infrared light source helps to directly visualize hydrogen-bonded molecules

Using a newly developed, ultrafast femtosecond infrared light source, chemists at the University of Chicago have been able to directly visualize the coordinated vibrations between hydrogen-bonded molecules -- the first time this sort of chemical interaction, which is found in nature everywhere at the molecular level, has been directly visualized.

16 Jul 2014

Viewpoints: 'Tradeoffs among access, quality and costs'; Obamacare as a political issue

One of the oft-repeated arguments in favor of the Affordable Care Act is that it will reduce people's need for more intensive care by increasing their access to preventive care.

16 Jul 2014

OSU creates new assay to test authenticity of primary drugs used to treat malaria

Chemists and students in science and engineering at Oregon State University have created a new type of chemical test, or assay, that's inexpensive, simple, and can tell whether or not one of the primary drugs being used to treat malaria is genuine - an enormous and deadly problem in the developing world.

16 Jul 2014

New avenues for treatment of Alzheimer's disease

Judes Poirier, PhD, C.Q., from the Douglas Mental Health Institute and McGill University in Montr-al (Canada) and his team have discovered that a relatively frequent genetic variant actually conveys significant protection against the common form of Alzheimer's disease and can delay the onset of the disease by as much as 4 years.

15 Jul 2014

Advanced Cell Diagnostics’ in situ hybridization technology reaches two major milestones

Advanced Cell Diagnostics Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, has announced that its RNAscope® RNA in situ hybridization technology has reached two major milestones. In just three years, over 100 peer-reviewed papers featuring the technology have been published, and with the significant increase in use of RNAscope, ACD has now built a library of over 4000 target probes for numerous species. Probes are designed to order in under two weeks, and in just six months the library has grown by over 1500, reflecting the wide interest in ACD’s breakthrough technology.

From Advanced Cell Diagnostics 15 Jul 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%.

15 Jul 2014

Pharmaceuticals News and Research

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

New article describes about crowdsourcing and drug repurposing needs

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

More insurers want you to see a doctor virtually

Single injection of protein FGF1 enough to restore blood sugar levels

Scientists build artificial cells programmed to eat their undesirable neighbors

Virobay announces closing of expanded Series B second tranche financing

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

Significant percentage of completed drug clinical trials are not disclosed to public

Research shows promise to speed up drug discovery for deadly diseases

Research sheds new light on brain's complicated barrier tissue

New femtosecond infrared light source helps to directly visualize hydrogen-bonded molecules

Viewpoints: 'Tradeoffs among access, quality and costs'; Obamacare as a political issue

OSU creates new assay to test authenticity of primary drugs used to treat malaria

New avenues for treatment of Alzheimer's disease

Advanced Cell Diagnostics’ in situ hybridization technology reaches two major milestones

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence